Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06011317 · ClinicalTrials.gov registry record · Phase 1
A Study of EDG-7500 in Healthy Adults
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT06011317 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 84 participants.
The verdict
NCT06011317, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purposes of this Phase 1 study of EDG-7500 are to: 1. Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults 2. Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults 3. Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-7500 in the blood is similar for the suspension and tablet forms of EDG-7500 in healthy adults Participants will receive a single or multiple doses of EDG-7500 or a placebo by mouth.
Interventions
- DRUG Placebo
- DRUG EDG-7500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06011317
The ClinicalTrials.gov registry entry for NCT06011317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06011317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06011317 about?
NCT06011317 is a clinical study titled "A Study of EDG-7500 in Healthy Adults". The purposes of this Phase 1 study of EDG-7500 are to: 1. Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults 2. Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults 3. Evaluate the amount of EDG-7500 is in the blood and urine...
What is the current status of trial NCT06011317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2023-08-14. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT06011317?
The interventions under investigation include: Placebo (DRUG), EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT06011317?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.